Brief: US FDA Approves Arcutis' Zoryve To Treat Atopic Dermatitis In Patients 6 Years Of Age And Older
09/07/2024 23:22
July 9 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* FDA APPROVES ARCUTIS’ ZORYVE® (ROFLUMILAST) CREAM 0.15%
FOR THE
TREATMENT OF ATOPIC DERMATITIS IN ADULTS AND CHILDREN DOWN TO 6
YEARS OF AGE
* ARCUTIS BIOTHERAPEUTICS INC - COMMERCIAL PRODUCT EXPECTED
TO BE
AVAILABLE BY END OF JULY
Source text for Eikon: ID:nGNX3xFXRF
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf